ClinicalTrials.gg
CompletedNCT03887130Updated Apr 30, 2024Results posted

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

A Phase 2 interventional study of oral vinorelbine and Capecitabine in Breast Cancer, sponsored by Pierre Fabre Medicament. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 years 6 months after the study started (first participant enrolled Mar 2007, registered Oct 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing vinorelbine in Breast Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. Vinorelbine · Breast Neoplasms.

Enrollment
17th of 97
152 · median 48
Started
2007
with 6 others
Phase 2
63 of 100
4 open now
Registered
75th of 100
by date

Among the 100 studies testing vinorelbine in Breast Neoplasms, this one is the 17th largest by enrollment of the 97 interventional ones that give a count, is one of 7 that started in 2007, is one of 63 in phase 2, and was the 75th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 100 studies testing vinorelbine in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vinorelbine

Vinorelbine: first FDA approval 1994 (NAVELBINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing vinorelbine in Breast Neoplasms, or all of them as a file.
02

Study summary

The aim of this international open-label randomized phase II trial is to evaluate the efficacy and safety of an all-oral combination and two all-intravenous combinations as first-line therapy for HER2-negative mBC patients.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the breast;
  • Documented disease previously untreated by chemotherapy;
  • negative (assessed by 0-1+ IHC or 2+ IHC with FISH-) on the primary tumor or on metastatic site;
  • Performance Status 70%.

Exclusion criteria

Exclusion Criteria:

  • Local relapse alone after conservative treatment or contra-lateral tumor;
  • Patients with symptoms suggesting CNS involvement or ;
  • Concomitant hormonal therapy for breast cancer;
  • Prior chemotherapy in the metastatic setting;
  • Patients previously treated with a vinca-alkaloid, capecitabine, gemcitabine or taxanes;
  • Prior severe and unexpected reaction to fluoropyrimidine therapy (with or without documented DPD deficiency) or known to 5-fluorouracil.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Vinorelbine-Capecitabine (arm A)

    oral vinorelbine (OV) with capecitabine (CAP)

    Drug: oral vinorelbine · Drug: Capecitabine

  • Active comparator
    Gemcitabine-Paclitaxel (arm B)

    gemcitabine (GEM) in combination with paclitaxel (PAC)

    Drug: Gemcitabine 1250 mg/m² · Drug: Paclitaxel

  • Active comparator
    Gemcitabine-Docetaxel (arm C)

    gemcitabine (GEM) in combination with docetaxel (DOC)

    Drug: Gemcitabine 1000 mg/m² · Drug: Docetaxel

Interventions

  • Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles

  • Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14

  • DrugGemcitabine 1250 mg/m²

    Drug page: Gemcitabine

    Gemcitabine 1250 mg/m² on day 1 \& day 8

  • DrugGemcitabine 1000 mg/m²

    Drug page: Gemcitabine

    Gemcitabine: 1000 mg/m² on day 1 \& 8

  • Paclitaxel 175 mg/m² on day 1

  • Docetaxel 75 mg/m² on day 1

06

What researchers measure

Primary outcomes

  1. Disease Control Rate (DCR)

    Disease control rate (DCR) defined as the sum of complete response, partial response and stable disease for at least 3 months according to RECIST criteria version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR)= Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable disease: no partial response or progression of the disease

    Time frame: From Baseline to disease progression or death, up to 6 years

07

Results

Posted Apr 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneVinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)
Started515051
Completed000
Not completed515051
Withdrew: Progressive disease23147
Withdrew: Protocol violation312
Withdrew: Drug related toxicity7713
Withdrew: Non drug related toxicity300
Withdrew: Death221
Withdrew: Withdrawal by subject7611
Withdrew: Other reason62017

Outcome measures

PrimaryDisease Control Rate (DCR)

Disease control rate (DCR) defined as the sum of complete response, partial response and stable disease for at least 3 months according to RECIST criteria version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR)= Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable disease: no partial response or progression of the disease

Time frame:
From Baseline to disease progression or death, up to 6 years
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsVinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)
Disease Control Rate (DCR)73.5 (58.9 to 85.1)78.0 (64.1 to 88.5)80.0 (66.3 to 90.0)

Adverse events

Collected over All adverse events were collected from the first dose of treatment through study completion up to 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vinorelbine-Capecitabine (Arm A)31/49 (63.3%)13/49 (26.5%)49/49 (100%)
Gemcitabine-Paclitaxel (Arm B)37/50 (74%)16/50 (32%)50/50 (100%)
Gemcitabine-Docetaxel (Arm C)35/50 (70%)12/50 (24%)50/50 (100%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventVinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)
VomitingGastrointestinal disorders5/491/501/50
DiarrhoeaGastrointestinal disorders4/491/501/50
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/490/501/50
NauseaGastrointestinal disorders3/491/503/50
PyrexiaGeneral disorders2/493/500/50
DyspnoeaRespiratory, thoracic and mediastinal disorders1/493/500/50
Pleural effusionRespiratory, thoracic and mediastinal disorders1/493/500/50
FatigueGeneral disorders0/493/501/50
ConstipationGastrointestinal disorders2/490/500/50
Hip fractureInjury, poisoning and procedural complications2/490/500/50
Most frequent other events
Showing 10 of 56
Most frequent other events
EventVinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)
FatigueGeneral disorders38/4935/5042/50
AlopeciaSkin and subcutaneous tissue disorders12/4938/5040/50
DiarrhoeaGastrointestinal disorders29/4913/5019/50
NauseaGastrointestinal disorders29/4919/5022/50
VomitingGastrointestinal disorders27/4912/5019/50
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders24/494/506/50
AnorexiaMetabolism and nutrition disorders19/4913/5017/50
DyspnoeaRespiratory, thoracic and mediastinal disorders18/4913/5017/50
Peripheral sensory neuropathyNervous system disorders12/4918/508/50
Abdominal painGastrointestinal disorders16/496/509/50

Baseline characteristics

Baseline characteristics are described for the Intent-to-treat population that consisted of all treated patients

Age, Continuous
Age, Continuous(years)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
Mean56.4 ± 9.756.0 ± 10.857.4 ± 9.756.6 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
Female495050149
Male0000
Body surface area
Body surface area(mg/m²)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
Mean1.8 ± 0.21.7 ± 0.21.8 ± 0.21.7 ± 0.2
Delay between diagnosis and study entry
Delay between diagnosis and study entry(years)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
Mean5.5 ± 5.75.8 ± 6.35.8 ± 5.95.7 ± 5.9
Primary tumour site
Primary tumour site(Participants)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
Bilateral3003
Left breast20242973
Right breast26262173
Delay between first relapse/progression and study entry
Delay between first relapse/progression and study entry(months)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
Mean8.8 ± 19.111.1 ± 29.811.3 ± 23.910.4 ± 24.5
Categorized number of organs involved at baseline
Categorized number of organs involved at baseline(Participants)Vinorelbine-Capecitabine (Arm A)Gemcitabine-Paclitaxel (Arm B)Gemcitabine-Docetaxel (Arm C)Total
1 organ93416
2 organs14251756
>= 3 organs26222977
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2007 to primary completion in Apr 2013, 72 months.

Results were first posted in Apr 2024, 11 years after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 72 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2016
First posted
Mar 22, 2019
StartActual
Mar 27, 2007
Primary completionActual
Apr 18, 2013
CompletionActual
Apr 18, 2013
Results first posted
Apr 30, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03887130
Responsible party
Sponsor
First posted
Mar 22, 2019
Start date
Mar 27, 2007
Primary completion
Apr 18, 2013
Completion
Apr 18, 2013
Results posted
Apr 30, 2024
Last update
Apr 30, 2024
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vinorelbine · Capecitabine · Gemcitabine

Start the discussion